Claims for Patent: 5,496,801
✉ Email this page to a colleague
Summary for Patent: 5,496,801
Title: | Parathyroid hormone formulation |
Abstract: | Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis. |
Inventor(s): | Holthuis; Josephus J. M. (AJ Leiden, NL), Mekking; Albert (CR Woerden, NL), Voetman; Alwinus A. (DT Zwanenburg, NL) |
Assignee: | Allelix BioPharmaceuticals Inc. (Ontario, CA) |
Application Number: | 08/172,206 |
Patent Claims: | 1. A parathyroid hormone preparation, comprising:
a medically useful amount of parathyroid hormone (1-84); a polyol excipient that co-lyophilizes with said hormone to yield an amorphous cake; a non-volatile buffering agent in an amount sufficient to adjust the pH of the preparation to within a physiologically acceptable pH range; and water. 2. A parathyroid hormone preparation according to claim 1, wherein said excipient is mannitol. 3. A parathyroid hormone formulation according to claim 1, wherein the buffering agent is a citrate source. 4. A parathyroid hormone formulation according to claim 3, wherein said excipient is mannitol. 5. A parathyroid hormone preparation according to claim 1, in the form of a freeze-dried powder containing not more than 2% water by weight. 6. A parathyroid hormone preparation according to claim 5, wherein the hormone is human PTH(1-84). 7. A parathyroid hormone preparation according to claim 6, wherein said excipient is mannitol. 8. A parathyroid hormone preparation according to claim 7, wherein the buffering agent is a citrate source. 9. A parathyroid hormone preparation according to claim 8, wherein said excipient is mannitol. 10. A parathyroid hormone preparation comprising parathyroid hormone (1-84) in a concentration within the range from 25 to 250 .mu.g/mL; mannitol in a concentration in the range from 3 to 7% (w/v); citrate buffer in an amount sufficient to adjust the pH of the preparation to within the range from pH 3.5 to pH 6.5; and water. 11. A parathyroid hormone preparation according to claim 10, wherein the parathyroid hormone is human PTH(1-84). 12. A parathyroid hormone preparation according to claim 11, in the form of a freeze-dried powder containing not more than 2% water by weight. 13. A parathyroid hormone preparation according to claim 12, wherein mannitol is present in a concentration within the range from 4 to 6%. 14. A parathyroid hormone preparation according to claim 13, wherein the citrate buffer is present in an amount sufficient to adjust the pH of the preparation to pH 6.+-.0.4. 15. A vial containing a parathyroid hormone preparation according to claim 1. 16. A vial containing a parathyroid hormone preparation according to claim 5. 17. A vial containing a parathyroid hormone preparation according to claim 9. 18. A vial containing a parathyroid hormone preparation according to claim 12. 19. A kit useful to formulate an injectable PTH solution, comprising at least one first vial containing a parathyroid hormone preparation as defined in claim 5, at least one second vial containing sterile water for reconstituting said preparation, and a sheet instructing preparation of a formulation therefrom. 20. The kit according to claim 19, further comprising a device for injection of the reconstituted PTH solution. 21. A parathyroid hormone preparation as claimed in claim 1, consisting of: a medically useful amount of parathyroid hormone (1-84); an excipient that co-lyophilizes with said hormone to yield an amorphous cake; a non-volatile buffering agent in an amount sufficient to adjust the pH of the preparation to within a physiologically acceptable pH range; and water. 22. A parathyroid hormone preparation as claimed in claim 1, consisting of: parathyroid hormone (1-84) in a concentration within the range from 25 to 250 .mu.g/mL; mannitol in a concentration in the range from 3 to 7% (w/v); citrate buffer in an amount sufficient to adjust the pH of the preparation to within the range from pH 3.5 to pH 6.5; and water. 23. A parathyroid hormone preparation as claimed in claim 1, wherein the polyol excipient and the non-volatile buffering agent are the only substances added to render the composition stable during storage. 24. A parathyroid hormone preparation as claimed in claim 10, wherein D-mannitol and citrate buffer are the only substances added to render the composition stable during storage. |
Details for Patent 5,496,801
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Llc | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | May 25, 2006 | ⤷ Sign Up | 2039-03-29 |
Takeda Pharmaceuticals U.s.a., Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | January 23, 2015 | ⤷ Sign Up | 2039-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,496,801
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9517207 | ⤷ Sign Up |
Slovakia | 82896 | ⤷ Sign Up |
Portugal | 735896 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.